MicroRNAs in cardiovascular disease: from pathogenesis to prevention and treatment

J Clin Invest. 2013 Jan;123(1):11-8. doi: 10.1172/JCI62876. Epub 2013 Jan 2.

Abstract

The management of cardiovascular risk through lifestyle modification and pharmacotherapy is paramount to the prevention of cardiovascular disease. Epidemiological studies have identified obesity, dyslipidemia, diabetes, and hypertension as interrelated factors that negatively affect cardiovascular health. Recently, genetic and pharmacological evidence in model systems has implicated microRNAs as dynamic modifiers of disease pathogenesis. An expanded understanding of the function of microRNAs in gene regulatory networks associated with cardiovascular risk will enable identification of novel genetic mechanisms of disease and inform the development of innovative therapeutic strategies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Cardiovascular Diseases / epidemiology
  • Cardiovascular Diseases / etiology
  • Cardiovascular Diseases / genetics*
  • Cardiovascular Diseases / metabolism*
  • Cardiovascular Diseases / therapy*
  • Diabetes Complications / epidemiology
  • Diabetes Complications / genetics
  • Diabetes Complications / metabolism
  • Diabetes Complications / therapy
  • Dyslipidemias / complications
  • Dyslipidemias / epidemiology
  • Dyslipidemias / genetics
  • Dyslipidemias / metabolism
  • Dyslipidemias / therapy
  • Humans
  • MicroRNAs / genetics*
  • MicroRNAs / metabolism*
  • Obesity / complications
  • Obesity / epidemiology
  • Obesity / genetics
  • Obesity / metabolism
  • Obesity / therapy
  • Risk Factors

Substances

  • MicroRNAs